• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[An improved exercise test in coronary-heart disease: effect of molsidomin on erogometrically controlled exercise (author's transl)].

作者信息

Blazek G, Heeger H, Kubicek F

出版信息

Dtsch Med Wochenschr. 1977 Jan 21;102(3):81-4. doi: 10.1055/s-0028-1104845.

DOI:10.1055/s-0028-1104845
PMID:832584
Abstract

The protective effect of molsidomin (N-ethoxycarbonyl-3-morpholinosydnonimine) during ergometric exercise was tested on 40 patients with coronary insufficiency proven by preliminary exercise tests or coronary arteriography. Changes in arterial blood pressure, heart rate, pulmonary artery pressure, ischaemic S-T depression and maximal working capacity were used as criteria. The drug increased maximal working capacity and decreased S-T segment depression. In addition it caused a fall in systolic and diastolic blood pressure and pulmonary artery pressure, at rest and during exercise. Resting heart rate increased slightly but during exercise the heart rate was reduced at comparable load stages. The results suggest that molsidomon may be an effective drug in the treatment of angina pectoris.

摘要

相似文献

1
[An improved exercise test in coronary-heart disease: effect of molsidomin on erogometrically controlled exercise (author's transl)].
Dtsch Med Wochenschr. 1977 Jan 21;102(3):81-4. doi: 10.1055/s-0028-1104845.
2
[Influence of molsidomine on exercise-ECG'S In coronary insufficiency (author's transl)].
Dtsch Med Wochenschr. 1977 Dec 2;102(48):1758-63. doi: 10.1055/s-0028-1105573.
3
[Action of molsidomine on haemodynamics at rest and on exercise in patients who have coronary heart disease (author's transl)].
Dtsch Med Wochenschr. 1978 May 19;103(20):853-6. doi: 10.1055/s-0028-1104774.
4
[Hemodynamic actions of molsidomin in coronary artery disease. Effects on regional myocardial blood flow, segmental ventricular wall motion, ejection phase parameters, ventricular volumes, systemic and pulmonary artery pressures and cardiac output (author's transl)].
Herz. 1979 Jun;4(3):285-92.
5
[The effect of molsidomin on the arterial windkessel (author's transl)].
Z Kardiol. 1981 Sep;70(9):713-8.
6
[Ergometric study of a new vasodilator agent in angina: molsidomine. Value of combination with beta-blockaders].[新型血管扩张剂莫西赛利治疗心绞痛的测力计研究:与β受体阻滞剂联合应用的价值]
Arch Mal Coeur Vaiss. 1981 Apr;74(4):463-71.
7
[The effect of molsidomine on left ventricular function in coronary heart disease (author's transl)].
Dtsch Med Wochenschr. 1980 Aug 29;105(35):1210-6. doi: 10.1055/s-2008-1070841.
8
[The normalizing effect of ECG in exercise tolerance tests under molsidomine in different dosages (author's transl].
Med Klin. 1978 Jun 30;73(26):983-6.
9
[Treatment of angina pectoris with molsidomin: results of a double-blind study for assessment of rate of anginal attacks, exercise reaction, and systolic time intervals (author's transl)].
Herz. 1978 Jun;3(3):172-84.
10
[Therapy of coronary heart disease with molsidomine].
MMW Munch Med Wochenschr. 1981 Nov 13;123(46):1761-2.

引用本文的文献

1
[Effect of molsidomine on hemodynamics and myocardial ischemia in patients with acute myocardial infarction (author's transl)].吗多明对急性心肌梗死患者血流动力学及心肌缺血的影响(作者译)
Klin Wochenschr. 1982 Jan 15;60(2):77-85. doi: 10.1007/BF01716385.
2
Increased effective vascular compliance and venous pooling of intravascular volume during sustained venodilation in conscious dogs.
Basic Res Cardiol. 1981 Nov-Dec;76(6):657-69. doi: 10.1007/BF01908056.
3
Haemodynamic effects of oral molsidomine in pump failure complicating myocardial infarction.
Eur J Clin Pharmacol. 1984;27(4):419-22. doi: 10.1007/BF00549588.
4
Haemodynamic effects of molsidomin.
Eur J Clin Pharmacol. 1978 Jun 19;13(4):241-5. doi: 10.1007/BF00716357.